Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - ciprofloxacin lactate - solution for infusion - 2 milligram(s)/millilitre - fluoroquinolones; ciprofloxacin

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - ciprofloxacin lactate - solution for infusion - 2 mg/ml - fluoroquinolones

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - ciprofloxacin - solution for infusion - 2 mg/ml, 100 millilitre(s) - fluoroquinolones; ciprofloxacin

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ciprofloxacin 2 mg/ml;   - solution for injection - 2 mg/ml - active: ciprofloxacin 2 mg/ml   excipient: glucose monohydrate lactic acid water for injection - hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life threatening infections due to sensitive organisms involving the following organ systems: - lower respiratory tract infections (gram-negative organisms) - skin and skin structure - septicaemia - bone and joint - urinary tract ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ciprofloxacin hydrochloride 111mg equivalent to ciprofloxacin 100 mg (anhydrous);  ;   - film coated tablet - 100 mg - active: ciprofloxacin hydrochloride 111mg equivalent to ciprofloxacin 100 mg (anhydrous)     excipient: colloidal silicon dioxide crospovidone hypromellose macrogols magnesium stearate maize starch microcrystalline cellulose opadry white y-22-7719 polydextrose pregelatinised maize starch purified water titanium dioxide triacetin - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ciprofloxacin hydrochloride 277.5mg equivalent to ciprofloxacin 250 mg (anhydrous);   - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 277.5mg equivalent to ciprofloxacin 250 mg (anhydrous)   excipient: colloidal silicon dioxide crospovidone hypromellose macrogols magnesium stearate maize starch microcrystalline cellulose opadry white y-22-7719 polydextrose pregelatinised maize starch purified water titanium dioxide triacetin - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ciprofloxacin hydrochloride 555mg equivalent to ciprofloxacin 500 mg (anhydrous);   - film coated tablet - 500 mg - active: ciprofloxacin hydrochloride 555mg equivalent to ciprofloxacin 500 mg (anhydrous)   excipient: colloidal silicon dioxide crospovidone hypromellose macrogols magnesium stearate maize starch microcrystalline cellulose opadry white y-22-7719 polydextrose pregelatinised maize starch purified water titanium dioxide triacetin - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ciprofloxacin hydrochloride 832.5mg equivalent to ciprofloxacin 750 mg (anhydrous);   - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 832.5mg equivalent to ciprofloxacin 750 mg (anhydrous)   excipient: colloidal silicon dioxide crospovidone hypromellose macrogols magnesium stearate maize starch microcrystalline cellulose opadry white y-22-7719 polydextrose pregelatinised maize starch purified water titanium dioxide triacetin - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.